Deakin University human schizophrenia research study into possible future schizophrenia treatment, using a tropical fruit called Mangosteen.
The Tropical fruit Mangosteen could be an effective treatment for Schizophrenia according to recently completed schizophrenia research. It is a tasty exotic fruit, yet the mangosteen might have a fringe Schizophrenia Treatment benefit in lowering the signs of schizophrenia.
A new scientific trial in Geelong explored the impact that mangosteen may have on schizophrenia signs and symptoms.
Mangosteens are an evergreen fruit from Indonesia with a thick, dark rind, or pericarp. The previous study into Schizophrenia Treatment indicates that potent antioxidants, xanthones and polyphenols, in the pericarp may provide a safe and effective treatment for schizophrenia with low negative effects.
Existing antipsychotic drugs are recognized to have extreme side effects, consisting of weight gain, which puts schizophrenia people in danger of other persistent ailments, such as diabetes and heart issues, and also decreasing quality of life.”Mental disorder impacts one in five people and also there is an excellent demand to give far better treatments for individuals that experience it,” said Dr Olivia Dean, Supervisor of Deakin University Clinical Test Department.
The study stems from research which has found evidence to suggest the rind (pericarp) of the fruit from the mangosteen contains bio-active compounds that may be beneficial in reducing inflammation and oxidative stress, which may, in turn, reduce the symptoms of Schizophrenia.
Dr Dean stated evidence suggested that the xanthones in the mangosteen pericarp may be beneficial in reducing oxidative anxiety, which may, in turn, decrease the signs experienced by those with schizophrenia. “Based on the understanding of the biology of schizophrenia, researchers think that the pericarp therapy might help in loading the space in between standard medications
Researchers recruited 150 individuals with schizo active symptoms over the two years in Geelong and Brisbane to take part in the Double-Blind clinical study
Participants took 2 x 500mg capsules a day, in addition to their prescribed medication for 24 weeks. Throughout that time, each person had several interviews to check their signs and symptoms and also examine whether pericarp therapy causes improvement. The group was split to 50/50 with half prescribed blind with the mangosteen and the other half issued blind with placebo.
“This special test might aid establish whether this simple supplement can have a positive result on the symptoms of schizophrenia condition,” claimed Teacher Michael Berk, psychoanalyst, and Director of Impact.
The clinical trials and study finished in the middle of 2019 and published papers are expected to be released in medical journals soon and will appear in our research section on this site. Mangosteen Dietary Supplements provided the researchers with the Mangosteen Substance used in this study.